Entering text into the input field will update the search result below

EXACT Sciences revenues up 144% in Q4; updates guidance

  • EXACT Sciences (NASDAQ:EXAS +13.3%) Q4 results: Revenues: $35.2M (+144.4%); Operating Loss: ($37.7M) (+6.7%); Net Loss: ($37.2M) (+7.0%); Loss Per Share: ($0.34) (+17.1%).
  • 2016 results: Revenues: $99.4M (+152.3%); Operating Loss: ($169M) (-6.2%); Net Loss: ($167.2M) (-6.0%); Loss Per Share: ($1.63) (+4.7%); Quick Assets: $311.1M (+1.4%).
  • 2017 Guidance: Revenues: $170M - 180M; Cologuard test volume:  at least 415,000.
  • Q1 Guidance: Cologuard test volume:88,000.

Recommended For You

About EXAS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EXAS--
Exact Sciences Corporation